Target type: biologicalprocess
Any process that results in a change in state or activity of a cell (in terms of movement, secretion, enzyme production, gene expression, etc.) as a result of a bisphenol A stimulus. [GO_REF:0000071, GOC:TermGenie, PMID:22957036]
Bisphenol A (BPA) is an endocrine disruptor that can interfere with the normal function of hormones in the body. Cellular response to BPA involves a complex interplay of signaling pathways, gene expression changes, and cellular processes. Here’s a detailed description:
1. **BPA Binding and Cellular Uptake:** BPA, due to its structural similarity to estrogen, can bind to estrogen receptors (ERs) in cells. It can also enter cells through passive diffusion.
2. **Estrogen Receptor Activation:** Upon binding to ERs, BPA can either activate or antagonize estrogen signaling. This depends on the specific ER subtype (α or β), cellular context, and BPA concentration.
3. **Signaling Pathways Modulation:** Activation of ERs by BPA can trigger a cascade of downstream signaling events, involving various signaling pathways, including:
* **Mitogen-activated protein kinase (MAPK) pathway:** This pathway is involved in cell proliferation, differentiation, and survival. BPA can activate MAPK signaling, potentially contributing to cellular growth and proliferation.
* **Phosphoinositide 3-kinase (PI3K)/Akt pathway:** This pathway regulates cell growth, survival, and metabolism. BPA can activate PI3K/Akt signaling, promoting cell survival and growth.
* **Nuclear factor kappa B (NF-κB) pathway:** This pathway plays a crucial role in inflammation, immune responses, and cell survival. BPA can activate NF-κB signaling, leading to increased inflammation and potential changes in immune responses.
4. **Gene Expression Regulation:** BPA can directly regulate gene expression by binding to ERs and influencing transcription. It can alter the expression of genes involved in various processes, including:
* **Cellular growth and proliferation:** BPA can upregulate the expression of genes involved in cell cycle progression, leading to increased cell growth.
* **Hormone metabolism:** BPA can alter the expression of genes involved in hormone synthesis, metabolism, and degradation, potentially disrupting hormonal balance.
* **Immune responses:** BPA can affect the expression of genes involved in immune cell activation and cytokine production, impacting immune function.
5. **Cellular Processes:** BPA can impact various cellular processes, including:
* **Cell cycle progression:** BPA can alter the timing of cell cycle phases, potentially leading to uncontrolled cell proliferation.
* **Apoptosis (programmed cell death):** BPA can either promote or inhibit apoptosis, depending on the cellular context.
* **Mitochondrial function:** BPA can interfere with mitochondrial function, potentially affecting energy production and oxidative stress.
* **Oxidative stress:** BPA can generate reactive oxygen species (ROS), contributing to oxidative stress and cellular damage.
6. **Long-term Effects:** Chronic exposure to BPA can lead to various long-term effects, including:
* **Endocrine disruption:** BPA can disrupt normal hormonal balance, leading to reproductive problems, developmental abnormalities, and metabolic disorders.
* **Cancer:** BPA has been linked to an increased risk of certain cancers, including breast, prostate, and endometrial cancer.
* **Neurodevelopmental disorders:** BPA has been associated with neurodevelopmental problems, including learning difficulties and attention deficit hyperactivity disorder (ADHD).
* **Cardiovascular disease:** BPA has been implicated in increased risk of cardiovascular disease due to its effects on blood pressure, cholesterol levels, and inflammation.
It's crucial to note that the specific effects of BPA on cellular responses can vary significantly depending on the cell type, exposure level, duration of exposure, and individual susceptibility. Further research is needed to fully understand the complex mechanisms and long-term consequences of BPA exposure.'
"
Protein | Definition | Taxonomy |
---|---|---|
DNA (cytosine-5)-methyltransferase 3A | A DNA (cytosine-5)-methyltransferase 3A that is encoded in the genome of human. [PRO:DNx, UniProtKB:Q9Y6K1] | Homo sapiens (human) |
Excitatory amino acid transporter 3 | An excitatory amino acid transporter 3 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P43005] | Homo sapiens (human) |
DNA (cytosine-5)-methyltransferase 1 | A DNA (cytosine-5)-methyltransferase 1 that is encoded in the genome of human. [PRO:DNx, UniProtKB:P26358] | Homo sapiens (human) |
Compound | Definition | Classes | Roles |
---|---|---|---|
alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid | alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid: An IBOTENIC ACID homolog and glutamate agonist. The compound is the defining agonist for the AMPA subtype of glutamate receptors (RECEPTORS, AMPA). It has been used as a radionuclide imaging agent but is more commonly used as an experimental tool in cell biological studies. | non-proteinogenic alpha-amino acid | |
procainamide | procainamide : A benzamide that is 4-aminobenzamide substituted on the amide N by a 2-(diethylamino)ethyl group. It is a pharmaceutical antiarrhythmic agent used for the medical treatment of cardiac arrhythmias. Procainamide: A class Ia antiarrhythmic drug that is structurally-related to PROCAINE. | benzamides | anti-arrhythmia drug; platelet aggregation inhibitor; sodium channel blocker |
vorinostat | vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL). Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME. | dicarboxylic acid diamide; hydroxamic acid | antineoplastic agent; apoptosis inducer; EC 3.5.1.98 (histone deacetylase) inhibitor |
cysteine | cysteine; cysteine zwitterion; L-alpha-amino acid; proteinogenic amino acid; serine family amino acid | EC 4.3.1.3 (histidine ammonia-lyase) inhibitor; flour treatment agent; human metabolite | |
aspartic acid | aspartic acid : An alpha-amino acid that consists of succinic acid bearing a single alpha-amino substituent Aspartic Acid: One of the non-essential amino acids commonly occurring in the L-form. It is found in animals and plants, especially in sugar cane and sugar beets. It may be a neurotransmitter. L-aspartic acid : The L-enantiomer of aspartic acid. | aspartate family amino acid; aspartic acid; L-alpha-amino acid; proteinogenic amino acid | Escherichia coli metabolite; mouse metabolite; neurotransmitter |
dichlone | dichlone: structure | ||
azacitidine | 5-azacytidine : An N-glycosyl-1,3,5-triazine that is 4-amino-1,3,5-triazin-2(1H)-one substituted by a beta-D-ribofuranosyl residue via an N-glycosidic linkage. An antineoplastic agent, it is used in the treatment of myeloid leukaemia. Azacitidine: A pyrimidine analogue that inhibits DNA methyltransferase, impairing DNA methylation. It is also an antimetabolite of cytidine, incorporated primarily into RNA. Azacytidine has been used as an antineoplastic agent. | N-glycosyl-1,3,5-triazine; nucleoside analogue | antineoplastic agent |
glutamic acid | glutamic acid : An alpha-amino acid that is glutaric acid bearing a single amino substituent at position 2. Glutamic Acid: A non-essential amino acid naturally occurring in the L-form. Glutamic acid is the most common excitatory neurotransmitter in the CENTRAL NERVOUS SYSTEM. | glutamic acid; glutamine family amino acid; L-alpha-amino acid; proteinogenic amino acid | Escherichia coli metabolite; ferroptosis inducer; micronutrient; mouse metabolite; neurotransmitter; nutraceutical |
epigallocatechin gallate | (-)-epigallocatechin 3-gallate : A gallate ester obtained by the formal condensation of gallic acid with the (3R)-hydroxy group of (-)-epigallocatechin. epigallocatechin gallate: a steroid 5alpha-reductase inhibitor and antimutagen in green tea (Camellia sinensis) | flavans; gallate ester; polyphenol | antineoplastic agent; antioxidant; apoptosis inducer; geroprotector; Hsp90 inhibitor; neuroprotective agent; plant metabolite |
5,5'-methylenedisalicylic acid | 5,5'-methylenedisalicylic acid: inhibits attachment of ribosomes to microsomal membranes; RN given refers to parent cpd; structure in first source & Merck Index, 9th ed, #5934 | ||
sym 2081 | |||
dihydrokainate | dicarboxylic acid | ||
s-tubercidinylhomocysteine | |||
6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octene | 6-bromo-3-(bromomethyl)-7-methyl-2,3,7-trichloro-1-octene: structure given in first source | monoterpenoid; organobromine compound; organochlorine compound | algal metabolite; antineoplastic agent; marine metabolite |
serine o-sulfate | L-serine O-sulfate : A non-proteinogenic L-alpha-amino acid that is the O-sulfo derivative of L-serine. serine O-sulfate: RN given refers to (L)-isomer | L-serine derivative; non-proteinogenic L-alpha-amino acid; O-sulfoamino acid | |
s-adenosyl-3-thiopropylamine | S-adenosyl-3-thiopropylamine : A thioadenosine that is adenosine in which the hydroxy group at C-5' is replaced by a 3-aminopropyl group. S-adenosyl-3-thiopropylamine: decarboxylated S-adenosylhomocysteine; RN given refers to parent cpd | organic sulfide; primary amino compound; thioadenosine | |
n(4)-adenosyl-n(4)-methyl-2,4-diaminobutanoic acid | |||
nsc 401077 | NSC 401077: inhibits DNA methyltransferase DNMT1; structure in first source | ||
s-adenosylhomocysteine | S-adenosyl-L-homocysteine : An organic sulfide that is the S-adenosyl derivative of L-homocysteine. S-Adenosylhomocysteine: 5'-S-(3-Amino-3-carboxypropyl)-5'-thioadenosine. Formed from S-adenosylmethionine after transmethylation reactions. | adenosines; amino acid zwitterion; homocysteine derivative; homocysteines; organic sulfide | cofactor; EC 2.1.1.72 [site-specific DNA-methyltransferase (adenine-specific)] inhibitor; EC 2.1.1.79 (cyclopropane-fatty-acyl-phospholipid synthase) inhibitor; epitope; fundamental metabolite |
hinokinin | hinokinin : A lignan that is dihydrofuran-2(3H)-one (gamma-butyrolactone) substituted by a 3,4-methylenedioxybenzyl group at positions 3 and 4 (the 3R,4R-diastereoisomer). hinokinin: suppresses expression of both HBsAg and HBeAg | benzodioxoles; gamma-lactone; lignan | trypanocidal drug |
3-hydroxyaspartic acid, (threo-l)-isomer | (3S)-3-hydroxy-L-aspartic acid : The (3S)-diastereomer of 3-hydroxy-L-aspartic acid. | 3-hydroxy-L-aspartic acid | metabolite |
decitabine | 2'-deoxyribonucleoside | ||
rg108 | RG108: DNA methyltransferase inhibitor; structure in first source | indolyl carboxylic acid | |
2-amino-3-phenylmethoxybutanedioic acid | aspartic acid derivative | ||
genistein | 7-hydroxyisoflavones | antineoplastic agent; EC 5.99.1.3 [DNA topoisomerase (ATP-hydrolysing)] inhibitor; geroprotector; human urinary metabolite; phytoestrogen; plant metabolite; tyrosine kinase inhibitor | |
dl-threo-beta-benzyloxyaspartate | |||
psammaplin a | psammaplin A: isolated from marine sponges Poecillastra and Jaspis; structure in second source | ||
l-beta-threo-benzyl-aspartate | L-beta-threo-benzyl-aspartate: structure in first source | ||
sgi-1027 | SGI-1027: inhibits DNA methyltransferase 1; structure in first source | ||
bix 01294 | piperidines | ||
ucph 101 | 2-amino-4-(4-methoxyphenyl)-7-(naphthalen-1-yl)-5-oxo-5,6,7,8-tetrahydro-4H-chromene-3-carbonitrile: structure in first source | ||
unc 0638 | UNC 0638: inhibits lysine methyltransferases G9a and GLP; structure in first source | quinazolines | |
gsk343 | GSK343 : A member of the class of indazoles that is 1-isopropyl-1H-indazole-4-carboxamide in which the nitrogen of the carboxamide group is substituted by a (6-methyl-2-oxo-4-propyl-1,2-dihydropyridin-3-yl)methyl group and in which the indazole ring is substituted at position 6 by a 2-(4-methylpiperazin-1-yl)pyridin-4-yl group. A highly potent and selective EZH2 inhibitor (IC50 = 4 nM). GSK343: an EZH2 methyltransferase inhibitor | aminopyridine; indazoles; N-alkylpiperazine; N-arylpiperazine; pyridone; secondary carboxamide | antineoplastic agent; apoptosis inducer; EC 2.1.1.43 (enhancer of zeste homolog 2) inhibitor |
6,7-dimethoxy-2-(pyrrolidin-1-yl)-n-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine | 6,7-dimethoxy-2-(pyrrolidin-1-yl)-N-(5-(pyrrolidin-1-yl)pentyl)quinazolin-4-amine: a SETD8 inhibitor; structure in first source |